Joseph R. Bertino, MD
Chief Scientific Officer, The Cancer Institute of New Jersey; Interim Director, The Stem Cell Institute of New Jersey; and University Professor of Medicine & Pharmacology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey
An outstanding investigator whose work has had a lasting effect on research, Dr. Bertino and colleagues reported early in his career the observation of gene amplification of DHFR, which opened a new era in drug-resistance research. Later, his work with methotrexate helped explain why some cancer drugs work and some fail. He has done important research on drug resistance in leukemia and soft-tissue sarcomas: Dr. Bertino found that almost a third of leukemia patients clinically resistant to methotrexate had low-level amplification of the dihydrofolate reductase gene. Using sensitive assays, his laboratory showed that impaired transport is a common mechanism of acquired resistance to methotrexate. These and other studies resulted in new analogues and new treatments being introduced in the clinic and brought him international recognition for his role in finding treatments for leukemia and lymphoma. His current studies are focused on finding new drug targets for tumor stem cells in prostate cancer.
Dr. Bertino is a translational researcher who seeks to build bridges between the laboratory and the clinic and an inspirational teacher and collaborator who has guided many of the current leaders in the field of cancer research. He is the founding editor-in-chief of Journal of Clinical Oncology.
2011 Jeffrey A. Gottlieb Memorial Award, UT MD Anderson Cancer Center2009 Outstanding Medical Research Scientist Award for Clinical Research, Edward J. Ill Excellence in Medicine Foundation, Inc.2008 AACR -Joseph H. Burchenal Memorial Award2008 John Ultman Award for Contributions to Lymphoma Research2006 Key to the Cure Award, Lymphoma Research Foundation2004 Freundlich Leadership Award, Lymphoma Research Foundation1995-1996 President, AACR1992 David A. Karnofsky Memorial Award, American Society of Clinical Oncology (ASCO)1990-2002 Chairman, Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Institute for Cancer Research1986-1990 Professor of Medicine and Pharmacology, Cornell University School of Medicine1978 AACR-Richard and Hinda Rosenthal Award1978 Jenaro Haddock Award, University of Puerto Rico1976-1979 Board of Directors, AACR1975 President, ASCO1973-1975 Director, Yale Comprehensive Cancer Center, Yale University School of Medicine1954 MD, Downstate Medical Center, Brooklyn